How did TrueHealth Medical perform on its HKEX debut?

Question

Accepted Answer

TrueHealth Medical Records Significant Surge on Hong Kong Stock Exchange Debut

Guangdong TrueHealth Medical Technology Development Co., Limited, trading as TrueHealth Medical, experienced a remarkable debut on the Main Board of the Hong Kong Stock Exchange on June 30, 2026. The company, the first specialist in percutaneous surgical robotics to list on the HKEX, saw its stock close at HK$400.0. This represented a substantial increase of HK$273.8 from its initial public offering (IPO) price of HK$126.2, marking a 216.96% surge on its first day of trading. The total trading volume for the day reached HK$320 million, with the company's market capitalization standing at HK$14.259 billion at the close of trading.
Strong Pre-Listing Sentiment Translated to Trading Performance

Investor interest in TrueHealth Medical was evident even before its official listing. Gray market sessions conducted by Futu Securities saw the stock peak at HK$358, a significant 183.7% premium over the IPO offer price. This robust pre-listing sentiment indicated strong investor appetite for the specialized segment of percutaneous puncture and ablation surgical robots, a niche market where TrueHealth Medical operates as a leader.
Market Leadership and Product Portfolio

TrueHealth Medical is recognized as China's market leader in percutaneous surgical robots, holding a 36.4% share by shipment volume and 28.0% by revenue in 2025, according to research by CIC Consulting. The company has developed a comprehensive product matrix, including four flagship percutaneous surgical robot variants: TH-S1, TH-S, TH-S Pro, and TH-SA. These systems have received Class III medical device registrations from China's National Medical Products Administration (NMPA), clearing them for use in percutaneous procedures on abdominal and pulmonary organs. The TH-S model is noted as a China-first innovation accredited by the NMPA.
Innovative Pipeline and Future Outlook

Beyond its existing robotic systems, TrueHealth Medical is advancing its pipeline with percutaneous microwave ablation robotics. Its TH-X MW system, approved for treating liver and lung tumors, has been recognized as a world-first innovation by the NMPA, while the TH-X HMW system is cleared for liver tumor interventions. The company's strategic listing on the HKEX provides capital to accelerate commercialization efforts, advance research and development for its current and future systems, and scale its manufacturing and go-to-market capabilities. This capital infusion is intended to support the company's transition from product validation to scaled commercial growth, focusing on an intelligent robotics portfolio for precision minimally invasive oncology solutions.

Reading history

Hide →

This history is cleared when the page is closed.

How did TrueHealth Medical perform on its HKEX debut?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends